The Association of the British Pharmaceutical Industry (ABPI) has issued a call for significant updates to the NHS Commercial Framework, emphasising the need for increased flexibility to support timely patient access to new medicines. The industry body argues that current arrangements may not be sufficiently agile to bring innovative treatments to those who need them most without undue delay.
The NHS Commercial Framework governs how the health service procures and funds medicines, setting out the terms under which pharmaceutical companies can supply their products. While designed to ensure value for money and consistent supply, the ABPI suggests that its present structure could inadvertently create barriers, slowing down the adoption of cutting-edge therapies in the UK compared to other nations.
A more adaptable framework, according to the ABPI, would allow for a broader range of commercial agreements, potentially including innovative payment models or risk-sharing arrangements that could accelerate the introduction of new drugs. This flexibility is seen as crucial for addressing the evolving landscape of medical innovation, where therapies are becoming increasingly complex and often target smaller patient populations with high unmet needs.
The implications of such changes could be far-reaching, potentially improving health outcomes for patients suffering from various conditions by reducing the wait times for new treatments. It also has economic implications for the UK's life sciences sector, as a more attractive market for new medicines could encourage further investment and research within the country.
While the Government and NHS England regularly review their procurement policies, the ABPI's intervention highlights a specific area where industry believes reform is essential. Any significant alteration to the framework would likely involve extensive consultation with stakeholders, including patient groups, healthcare professionals, and pharmaceutical companies, to balance the need for innovation with financial sustainability for the NHS.